Paragon Bioservices Appoints Dr. Vadim Klyushnichenko as Vice President of Preclinical Services and Process Development
Published: Jul 20, 2011
BALTIMORE, July 20, 2011 /PRNewswire/ -- Paragon Bioservices, Inc., a Baltimore-based contract research and GMP manufacturing organization, announced today the appointment of Vadim Klyushnichenko, Ph.D. as Vice President, Preclinical Services and Process Development. He will report to Paragon's President and CEO Marco Chacon, Ph.D.
Dr. Klyushnichenko has more than 15 years experience in biopharmaceutical project management, analytical development and formulation, process development, engineering and scale-up from pilot to GMP manufacturing, technology transfer and regulatory filing.
He developed his managerial and scientific background working as Vice President of Drug Development at both Terapio (Austin, TX) and Coldstream Laboratories, Lab Head at Wyeth BioPharma, and Senior Scientist positions at Epic Therapeutics (Baxter), Altus Biologics in Boston and Aventis/Sanofi Pasteur.
Dr. Klyushnichenko received his M.S., Engineering from Moscow Institute of Physics and Technology, and a Ph.D. in Chemistry from the Shemyakin Institute of Bioorganic Chemistry in Moscow. His additional research in Analytical Biochemistry and Process Development includes the Humboldt University in Berlin, Dusseldorf University, and the Biotechnology Research Institute in Montreal. He is also a Certified Professional Project Manager (PMP/PMI) and holds a Certificate of Special Studies (CSS) in Administration and Management from Harvard University.
Dr. Chacon stated, "We feel that Vadim will be a great addition to Paragon's team as we continue to add personnel, double our process development and GMP manufacturing and add fill-and-finish capabilities to our facility."
About Paragon Bioservices
Paragon Bioservices is a contract research and manufacturing organization (CMO) that provides a comprehensive portfolio of servicesfrom research services and process development to cGMP manufacturing of monoclonal antibodies, therapeutic proteins, vaccines and VLPs, and stem cells. The corporate focus is to bridge the translational divide and enable protein and cell-based therapeutics to move into clinical trials.
SOURCE Paragon Bioservices, Inc.